Economic assessment of drugs for rare diseases: Must it be done, if yes, which are its features?

The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Search result: 0

Plavinskii S.L.

Federal state budgetary educational Institution of higher professional education «I.I. Mechnikov North-Western State Medical University», Ministry of Health of the Russian Federation, Saint-Petersburg, Russia

Economic assessment of drugs for rare diseases: Must it be done, if yes, which are its features?

Authors:

Plavinskii S.L.

More about the authors

Journal: Therapeutic Archive. 2014;86(12): 13‑18

Read: 673 times

Contact the author

Table of contents

To cite this article:

Plavinskii SL. Economic assessment of drugs for rare diseases: Must it be done, if yes, which are its features? Therapeutic Archive. 2014;86(12):13‑18.

Использование инфографики авторами научных работ

Close metadata

Abstract:

The orphan drug laws enacted firstly in the USA and then in some other countries have given rise to a specific market of drugs for rare diseases and to a drastic increase in the number of proposed drugs. At the same time, the prices for innovative drugs are frequently high, have resulted in debates about their cost effectiveness and the drugs for rare diseases being frequently difficult to be tested for their efficacy due to disease rarity. The article discusses the designs of clinical trials that could enhance their effectiveness, gives examples of standard-design trials, and notes that effectiveness evaluations can be obtained for most diseases, but with a small sample, they will not be very precise, which makes cost-effectiveness analysis difficult. In this connection, a number of mechanisms proposed worldwide to solve the existing situation are discussed.

Keywords:

rare (orphan) disease

clinical trial design; cost-effectiveness analysis; quality- adjusted life years; reimbursement schemes

Authors:

Plavinskii S.L.

Federal state budgetary educational Institution of higher professional education «I.I. Mechnikov North-Western State Medical University», Ministry of Health of the Russian Federation, Saint-Petersburg, Russia

Close metadata

References:

Lachmann P.J. The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals. QJM 2012; 105 (12): 1179-1189.
Committee on Accelerating Rare Diseases Research and Orphan Product Development. Rare Diseases and Orphan Products: Accelerating Research and Development/Committee on Accelerating Rare Diseases Research and Orphan Product Development; Ed. by T.F. Boat, M.J. Field. Washington, D.C.: National Academies Press; 2011.
Kilcoyne A., O'Connor D., Ambery P. Pharmaceutical Medicine. Oxford: Oxford University Press; 2013.
McCabe C., Claxton K., Tsuchiya A. Orphan drugs and the NHS: should we value rarity? BMJ 2005; 331 (7523): 1016-1019.
Hughes D.A., Tunnage B., Yeo S.T. Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM 2005; 98 (11): 829-836.
Simoens S., Cassiman D., Dooms M., Picavet E. Orphan drugs for rare diseases: is it time to revisit their special market access status? Drugs 2012; 72 (11): 1437-1443.
Appel L.J. A primer on the design, conduct, and interpretation of clinical trials. Clin J Am Soc Nephrol 2006; 1 (6): 1360-1367.
Wilcken B. Rare diseases and the assessment of intervention: what sorts of clinical trials can we use? J Inherit Metab Dis 2001; 24 (2): 291-298.
Edwards S.J., Lilford R.J., Braunholtz D., Jackson J. Why "underpowered" trials are not necessarily unethical. Lancet 1997; 350 (9080): 804-807.
Griffiths M. "Underpowered" trials. Lancet 1997; 350 (9088): 1406.
Lilford R.J., Thornton J.G., Braunholtz D. Clinical trials and rare diseases: a way out of a conundrum. BMJ 1995; 311 (7020): 1621-1625.
Pocock S.J., Elbourne D.R. Randomized trials or observational tribulations? N Engl J Med 2000; 342 (25): 1907-1909.
Needham M., Corbett A., Day T. et al. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J Clin Neurosci 2008; 15 (12): 1350-1353.
Gallin J.I., Alling D.W., Malech H.L. et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med 2003; 348 (24): 2416-2422.
Sacks H., Chalmers T.C., Smith H. Randomized versus historical controls for clinical trials. Am J Med 1982; 72 (2): 233-240.
Guyatt G., Sackett D., Taylor D.W. et al. Determining optimal therapy - randomized trials in individual patients. N Engl J Med 1986; 314 (14): 889-892.
Reitberg D.P., Weiss S.L., del Rio E. Advances in single-patient trials for drug treatment optimization and risk management. Drug Inform J 2005; 39 (2): 119-124.
Rosenberger W.F. Randomized play-the-winner clinical trials: review and recommendations. Control Clin Trials 1999; 20 (4): 328-342.
Dragalin V. Adaptive designs: terminology and classification. Drug Inform J 2006; 40 (4): 425-435.
Richey E.A., Lyons E.A., Nebeker J.R. et al. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? J Clin Oncol 2009; 27 (26): 4398-4405.
Mitsumoto J., Dorsey E.R., Beck C.A. et al. Pivotal studies of orphan drugs approved for neurological diseases. Ann Neurol 2009; 66 (2): 184-190.
Griggs R.C., Batshaw M., Dunkle M. et al. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab 2009; 96 (1): 20-26.
Orfali M., Feldman L., Bhattacharjee V. et al. Raising orphans: how clinical development programs of drugs for rare and common diseases are different. Clin Pharmacol Ther 2012; 92 (2): 262-264.
Bashaw E.D., Huang S.M., Cote T.R. et al. Clinical pharmacology as a cornerstone of orphan drug development. Nat Rev Drug Discov 2011; 10 (11): 795-796.
Bashaw E.D., Fang L. Clinical pharmacology and orphan drugs: an informational inventory 2006-2010. Clin Pharmacol Ther 2012; 91 (5): 932-936.
Kanters T.A., de Sonneville-Koedoot C., Redekop W.K., Hakkaart L. Systematic review of available evidence on 11 high-priced inpatient orphan drugs. Orphanet J Rare Dis 2013; 8 (1): 124.
Putzeist M., Heemstra H.E., Garcia J.L. et al. Determinants for successful marketing authorisation of orphan medicinal products in the EU. Drug Discov Today 2012; 17 (7-8): 352-358.
NICE. Appraising Orphan Drugs. London: National Institute for Health and Clinical Excellence; 2005; 9.
Meekings K.N., Williams C.S., Arrowsmith J.E. Orphan drug development: an economically viable strategy for biopharma R&D. Drug Discov Today 2012; 17 (13-14): 660-664.
Rollet P., Lemoine A., Dunoyer M. Sustainable rare diseases business and drug access: no time for misconceptions. Orphanet J Rare Dis 2013; 8: 109.
Moldrup C. No cure, no pay. BMJ 2005; 330 (7502): 1262-1264.
Chapman S., Reeve E., Rajaratnam G., Neary R. Setting up an outcomes guarantee for pharmaceuticals: new approach to risk sharing in primary care. BMJ 2003; 326 (7391): 707-709.

Log in to the site using your account in one of the services

Registration

Last Name

Name

Middle Name

E-mail

Phone

Address

Country

Zip

City

Region

Street

Home

Apartmen

Legal entity name

ИНН

КПП

Password

Password

Repeat password

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.